Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by biorunon Apr 02, 2024 5:01pm
112 Views
Post# 35966199

RE:Sirona Corporation has a virus infection!

RE:Sirona Corporation has a virus infection!Frustration is abound, rightly so based upon a lack of transparency on a variety of fronts - whether it be them not releasing the juicy details of the AbbVie agreement or pertinent updates on the new discovery on sglt2 or equity partner pursuits on anti aging.

I am not sure that either Chris or Howard are proactive on the communications front. That idea died with Michelle.

What that means is that information voids can create pressure on bid like we are seeing, perhaps even when it is entirely possible they are making important strides on these fronts. 

My view at this point is that if one believes they reasonably continue to keep the heat and lights on, long enough to see new products to hit street as anticipated, then these low trading ranges represent an absolutely phenomenal entry point.  The minute we get clarity on the financing in place for the anti aging rollout, then this could present an immediate and potentially shocking upswing with a double, triple or more scenario as this would represent the moment this idea/plan etc has actual real legs with accountability attached. That said, we could continue to slog along. 


<< Previous
Bullboard Posts
Next >>